Our strategy of repurposing rosiglitazone to prime NECTIN4 expression across a population of tumor cells with low to moderate expression significantly enhanced anti-tumor activity of NECTIN4-targeting CAR T therapy. The gene discussed is NECTIN4; the disease is neoplasm.